Novo Nordisk’s semaglutide demonstrates superior weight loss versus placebo in STEP 4 trial

This is significant for the global obesity market, where Novo Nordisk’s Saxenda (liraglutide) currently occupies a 55% market share. Credit: Shutterstock + joreks



  • novo nordisk